Literature DB >> 12946993

Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.

Philippe Guardiola1, Gérard Socié, Xiaxin Li, Patricia Ribaud, Agnés Devergie, Hélène Espérou, Patrice Richard, Richard Traineau, Anne Janin, Eliane Gluckman.   

Abstract

To assess whether Fanconi anemia (FA) patients might be at risk for acute graft-versus-host disease (AGvHD) despite using low-intensity conditionings, we retrospectively analyzed the incidence of AGvHD and its impact on outcome in 37 FA patients and 73 patients with acquired aplastic anemia (AAA) that received transplants at Saint Louis Hospital from HLA-genotypic identical siblings with similar conditionings (thoraco-abdominal irradiation plus cyclophosphamide 20 [FA] or 150 mg/kg [AAA]). Despite being younger, FA patients had an increased risk of grades II to IV AGvHD (relative risk [RR], 2.00; P =.021), especially in younger patients (RR, 7.93; P =.014). The risks of requiring systemic corticosteroids to treat AGvHD and experiencing cortico-resistant AGvHD were significantly increased in FA patients. Although non-FA and FA patients had similar 10-year outcomes, acute and chronic GvHD had a biphasic effect on FA patient outcome with an additional cluster of lethal events starting by 5 years after transplantation. This late survival fall, restricted to FA patients, was closely related to head and neck carcinomas (15-year incidence: 53%). FA patients represent a group at risk regarding AGvHD when using irradiation-based conditionings. The impact of AGvHD on survival may not be limited to the early posttransplantation period and may be a major risk factor for head and neck carcinomas and late mortality in FA patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946993     DOI: 10.1182/blood-2003-06-2146

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma.

Authors:  Andrew C Birkeland; Arleen D Auerbach; Erica Sanborn; Bhupesh Parashar; William I Kuhel; Settara C Chandrasekharappa; Agata Smogorzewska; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-09

2.  Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up.

Authors:  David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska
Journal:  Laryngoscope       Date:  2015-10-20       Impact factor: 3.325

3.  HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.

Authors:  Ricardo Pasquini; Jeanette Carreras; Marcelo C Pasquini; Bruce M Camitta; Anders L Fasth; Gregory A Hale; Richard E Harris; Judith C Marsh; Anibal J Robinson; Mei-Jie Zhang; Mary Eapen; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

4.  Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Authors:  Parinda A Mehta; Chie Emoto; Tsuyoshi Fukuda; Brian Seyboth; Ashley Teusink-Cross; Stella M Davies; Jamie Wilhelm; Kirsten Fuller; Alexander A Vinks; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

Review 5.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

6.  Alternative donor hematopoietic cell transplantation for Fanconi anemia.

Authors:  Margaret L MacMillan; Todd E DeFor; Jo-Anne H Young; Kathryn E Dusenbery; Bruce R Blazar; Arne Slungaard; Heather Zierhut; Daniel J Weisdorf; John E Wagner
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

7.  Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.

Authors:  Christen L Ebens; Todd E DeFor; Rebecca Tryon; John E Wagner; Margaret L MacMillan
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-02       Impact factor: 5.742

Review 8.  Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.

Authors:  Andrew C Dietz; Sharon A Savage; Adrianna Vlachos; Parinda A Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

9.  HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.

Authors:  Carmem M Bonfim; Carlos R de Medeiros; Marco A Bitencourt; José Zanis-Neto; Vaneuza A M Funke; Daniela C Setubal; Jefferson Ruiz; Jean E Sanders; Mary E D Flowers; Hans-Peter Kiem; Rainer Storb; Ricardo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2007-10-18       Impact factor: 5.742

10.  Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture.

Authors:  E E Hoskins; T A Morris; J M Higginbotham; N Spardy; E Cha; P Kelly; D A Williams; K A Wikenheiser-Brokamp; S Duensing; S I Wells
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.